MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

24.92 -0.12 (-0.47%)
Streaming Delayed Price Updated: 2:20 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Proposed Public Offering of Ordinary Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Outlines 2025 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and... 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Data at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story